Finch Therapeutics Group, Inc. announced plans to reduce its workforce by approximately 37% as part of an ongoing strategic review of its business and portfolio. This decision follows Finch's recent announcement that it is assessing the financial and strategic impact of Takeda's decision to discontinue its inflammatory bowel disease (IBD) collaboration with Finch. The company will provide further updates on the strategy for each of its product candidates and its cash runway in the future.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.92 USD | -8.57% | -9.43% | -46.81% |
1st Jan change | Capi. | |
---|---|---|
-46.81% | 3.37M | |
+33.37% | 49.46B | |
+1.55% | 42.58B | |
+49.11% | 42.49B | |
-4.22% | 29.09B | |
+11.57% | 26.61B | |
-21.00% | 18.64B | |
+7.36% | 13.16B | |
+28.30% | 12.55B | |
+23.80% | 12.1B |
- Stock Market
- Equities
- FNCH Stock
- News Finch Therapeutics Group, Inc.
- Finch Therapeutics Group, Inc. Plans to Reduce its Workforce by Approximately 37%